Skip to main content
SpringerLink
Log in

Myocardial Infarction: Cardioprotection by Erythropoietin

  • Protocol
  • First Online:
Tissue-Protective Cytokines

Part of the book series: Methods in Molecular Biology ((MIMB,volume 982))

Abstract

Extensive research during the last decade demonstrated that a single systemic administration of ­erythropoietin (EPO) lead to significant attenuation of myocardial infarction (MI) induced in animals, mostly small rodents, either by a myocardial ischemia followed by reperfusion or by a permanent ligation of a coronary artery. Both methods are critically reviewed with the aim of helping the reader in appreciating key issues in the translation of experimental results to the clinic. Results of several clinical trials in patients with acute MI completed to date failed to demonstrate beneficial effects of EPO, and thus put into question the validity of results obtained in animal models. Comprehensive review of design and results of animal experiments and clinical trials presented here allowed authors to postulate that therapeutic window for EPO during developing MI is very narrow and was possibly missed in negative clinical trials. This point was illustrated by the negative outcome of experiment in the rat model of MI in which timing of EPO administration was similar to that in clinical trials. The design of future clinical trials should allow for a narrow therapeutic window of EPO. Given current standards for onset-to-door and door-to-balloon time the optimal time for EPO administration should be just prior to PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bogoyevitch MA (2004) An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63(2):208–216, Review

    Article  PubMed  CAS  Google Scholar 

  2. Koul D, Dhar S, Chen-Scarabelli C, Guglin M, Scarabelli TM (2007) Erythropoietin: new horizon in cardiovascular medicine. Recent Pat Cardiovasc Drug Discov 2(1):5–12, Review

    Article  PubMed  CAS  Google Scholar 

  3. Riksen NP, Hausenloy DJ, Yellon DM (2008) Erythropoietin: ready for prime-time cardioprotection. Trends Pharmacol Sci 29(5):258–267, Review

    Article  PubMed  CAS  Google Scholar 

  4. Latini R, Brines M, Fiordaliso F (2008) Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 13(4):415–423, Review

    Article  PubMed  CAS  Google Scholar 

  5. Vogiatzi G, Briasoulis A, Tousoulis D, Papageorgiou N, Stefanadis C (2010) Is there a role for erythropoietin in cardiovascular disease? Expert Opin Biol Ther 10(2):251–264, Review

    Article  PubMed  CAS  Google Scholar 

  6. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48(11):2161–2167, Epub 2006 Nov 9. Review

    Article  PubMed  CAS  Google Scholar 

  7. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N (2003) Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308(4):990–994

    Article  PubMed  CAS  Google Scholar 

  8. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, Talan MI (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 100(20):11612–11617

    Article  PubMed  CAS  Google Scholar 

  9. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI (2005) Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc Drugs Ther 19(4):243–250

    Article  PubMed  CAS  Google Scholar 

  10. Moon C, Krawczyk M, Lakatta EG, Talan MI (2006) Therapeutic effectiveness of a single vs. multiple doses of erythropoietin after ­experimental myocardial infarction in rats. Cardiovasc Drugs Ther 20(4):245–251

    Article  PubMed  CAS  Google Scholar 

  11. Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, Sollott SJ, Lakatta EG, Talan MI (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316(3):999–1005

    Article  PubMed  CAS  Google Scholar 

  12. Ahmet I, Tae HJ, Juhaszova M, Riordon DR, Boheler KR, Sollott SJ, Brines M, Cerami A, Lakatta EG, Talan MI (2011) A small non-erythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 17(3–4):194–200. doi:10.2119/molmed.2010.00235

    PubMed  CAS  Google Scholar 

  13. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112(7):999–1007

    PubMed  CAS  Google Scholar 

  14. van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2005) Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46(1):125–133

    Article  PubMed  Google Scholar 

  15. Hale SL, Sesti C, Kloner RA (2005) Administration of erythropoietin fails to improve long-term healing or cardiac function after myocardial infarction in the rat. J Cardiovasc Pharmacol 46(2):211–215

    Article  PubMed  CAS  Google Scholar 

  16. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, Tsukamoto O, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Shiraga M, Kitakaze M, Hori M (2006) Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48(1):176–184, Epub 2006 Jun 2

    Article  PubMed  CAS  Google Scholar 

  17. Chua S, Leu S, Lin YC, Sheu JJ, Sun CK, Chung SY, Chai HT, Lee FY, Kao YH, Wu CJ, Chang LT, Ko SF, Yip HK (2011) Early erythropoietin therapy attenuates remodeling and preserves function of left ventricle in porcine myocardial infarction. J Investig Med 59(3):574–586

    PubMed  CAS  Google Scholar 

  18. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802–4806

    Article  PubMed  CAS  Google Scholar 

  19. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ (2004) Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279:20655–20662

    Article  PubMed  CAS  Google Scholar 

  20. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM, Thiemermann C (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22:63–69

    Article  PubMed  CAS  Google Scholar 

  21. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2004) Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473–479

    Article  PubMed  CAS  Google Scholar 

  22. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel ED, Xenocostas A, Kvietys PR (2005) Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65:719–727

    Article  PubMed  CAS  Google Scholar 

  23. Hirata A, Minamino T, Asanuma H, Sanada S, Fujita M, Tsukamoto O, Wakeno M, Myoishi M, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Tomoike H, Hori M, Kitakaze M (2005) Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 19:33–40

    Article  PubMed  CAS  Google Scholar 

  24. Xu B, Dong GH, Liu H, Wang YQ, Wu HW, Jing H (2005) Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappa B. Ann Clin Lab Sci 35:161–168

    PubMed  CAS  Google Scholar 

  25. Bullard AJ, Govewalla P, Yellon DM (2005) Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397–403

    Article  PubMed  CAS  Google Scholar 

  26. Kristensen J, Maeng M, Rehling M, Berg JS, Mortensen UM, Nielsen SS, Nielsen TT (2005) Lack of acute cardioprotective effect from pre-ischaemic erythropoietin administration in a porcine coronary occlusion model. Clin Physiol Funct Imaging 25:305–310

    Article  PubMed  CAS  Google Scholar 

  27. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, Xu J (2006) Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78:2255–2264

    Article  PubMed  CAS  Google Scholar 

  28. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K (2006) Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 291:H748–H755

    Article  PubMed  CAS  Google Scholar 

  29. Olea FD, Vera Janavel G, De Lorenzi A, Cuniberti L, Yannarelli G, Cabeza Meckert P, Cearras M, Laguens R, Crottogini A (2006) High-dose erythropoietin has no long-term protective effects in sheep with reperfused myocardial infarction. J Cardiovasc Pharmacol 47:736–741

    Article  PubMed  CAS  Google Scholar 

  30. Liu X, Zhou Z, Feng X, Jia Z, Jin Y, Xu J (2006) Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats. Postgrad Med J 82:588–593

    Article  PubMed  CAS  Google Scholar 

  31. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ (2007) Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 293:H60–H68

    Article  PubMed  CAS  Google Scholar 

  32. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell JS, Gross GJ (2007) Darbepoetin-alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms. J Cardiovasc Pharmacol 49:337–345

    Article  PubMed  CAS  Google Scholar 

  33. Toma C, Letts DP, Tanabe M, Gorcsan J III, Counihan PJ (2007) Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol 43:130–136

    Article  PubMed  CAS  Google Scholar 

  34. Singh D, Kolarova JD, Wang S, Ayoub IM, Gazmuri RJ (2007) Myocardial protection by erythropoietin during resuscitation from ventricular fibrillation. Am J Ther 14:361–368

    Article  PubMed  Google Scholar 

  35. Boucher M, Pesant S, Lei YH, Nanton N, Most P, Eckhart AD, Koch WJ, Gao E (2008) Simultaneous administration of insulin-like growth factor-1 and darbepoetin-alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci 1:13–20

    Article  PubMed  CAS  Google Scholar 

  36. Prunier F, Pottier P, Clairand R, Mercier A, Hajjar RJ, Planchon B, Furber A (2009) Chronic erythropoietin treatment decreases post-infarct myocardial damage in rats without venous thrombogenic effect. Cardiology 112:129–134

    Article  PubMed  CAS  Google Scholar 

  37. Shan X, Xu X, Cao B, Wang Y, Guo L, Zhu Q, Li J, Que L, Chen Q, Ha T, Li C, Li Y (2009) Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotection against myocardial ischemia/reperfusion injury. Int J Cardiol 134:384–392

    Article  PubMed  Google Scholar 

  38. Doue T, Ohtsuki K, Ogawa K, Ueda M, Azuma A, Saji H, Strauss HW, Matsubara H (2008) Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of infarct size with 99mTc-annexin V. J Nucl Med 49:1694–1700

    Article  PubMed  CAS  Google Scholar 

  39. Huang CH, Hsu CY, Tsai MS, Wang TD, Chang WT, Chen WJ (2008) Cardioprotective effects of erythropoietin on post-resuscitation myocardial dysfunction in appropriate therapeutic windows. Crit Care Med 36:S467–S473

    Article  PubMed  Google Scholar 

  40. Burger D, Xiang F, Hammoud L, Lu X, Feng Q (2009) Role of heme oxygenase-1 in the cardioprotective effects of erythropoietin during myocardial ischemia and reperfusion. Am J Physiol Heart Circ Physiol 296:H84–H93

    Article  PubMed  CAS  Google Scholar 

  41. Burger DE, Xiang FL, Hammoud L, Jones DL, Feng Q (2009) Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase. J Pharmacol Exp Ther 329:900–907

    Article  PubMed  CAS  Google Scholar 

  42. French CJ, Zaman AK, Sobel BE (2009) Failure of erythropoietin to render jeopardized ischemic myocardium amenable to incremental salvage by early reperfusion. Coron Artery Dis 20:295–299

    Article  PubMed  Google Scholar 

  43. Schlecht-Bauer D, Antier D, Machet MC, Hyvelin JM (2009) Short- and long-term cardioprotective effect of darbepoetin-alpha: role of Bcl-2 family proteins. J Cardiovasc Pharmacol 54:223–231

    Article  PubMed  CAS  Google Scholar 

  44. Tamareille S, Ghaboura N, Treguer F, Khachman D, Croué A, Henrion D, Furber A, Prunier F (2009) Myocardial reperfusion injury management: erythropoietin compared with postconditioning. Am J Physiol Heart Circ Physiol 297:H2035–H2043

    Article  PubMed  CAS  Google Scholar 

  45. Miki T, Miura T, Hotta H, Tanno M, Yano T, Sato T, Terashima Y, Takada A, Ishikawa S, Shimamoto K (2009) Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition. Diabetes 58:2863–2872

    Article  PubMed  CAS  Google Scholar 

  46. Hotta H, Miura T, Miki T, Togashi N, Maeda T, Kim SJ, Tanno M, Yano T, Kuno A, Itoh T, Satoh T, Terashima Y, Ishikawa S, Shimamoto K (2010) Angiotensin II type 1 receptor-­mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts. Circ Res 106:129–132

    Article  PubMed  CAS  Google Scholar 

  47. Treguer F, Donal E, Tamareille S, Ghaboura N, Derumeaux G, Furber A, Prunier F (2010) Speckle tracking imaging improves in vivo assessment of EPO-induced myocardial salvage early after ischemia-reperfusion in rats. Am J Physiol Heart Circ Physiol 298:H1679–H1686

    Article  PubMed  CAS  Google Scholar 

  48. Shen Y, Wang Y, Li D, Wang C, Xu B, Dong G, Huang H, Jing H (2010) Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc 42:1595–1597

    Article  PubMed  CAS  Google Scholar 

  49. Stein A, Knödler M, Makowski M, Kühnel S, Nekolla S, Keithahn A, Weidl E, Groha P, Schürmann M, Saraste A, Botnar R, Oostendorp RA, Ott I (2010) Local erythropoietin and endothelial progenitor cells improve regional cardiac function in acute myocardial infarction. BMC Cardiovasc Disord 10:43

    Article  PubMed  Google Scholar 

  50. Yano T, Miki T, Tanno M, Kuno A, Itoh T, Takada A, Sato T, Kouzu H, Shimamoto K, Miura T (2011) Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection. Hypertension 57:110–115

    Article  PubMed  CAS  Google Scholar 

  51. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 64(4):412–423

    Article  PubMed  CAS  Google Scholar 

  52. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Rüther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Sirén AL (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8(8):495–505

    PubMed  CAS  Google Scholar 

  53. Tang YD, Hasan F, Giordano FJ, Pfau S, Rinder HM, Katz SD (2009) Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: results of a double-blind, placebo-controlled, randomized trial. Am Heart J 158(6):941–947

    Article  PubMed  CAS  Google Scholar 

  54. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, van Zonneveld AJ, Schoemaker RG, van Gilst WH, Zijlstra F, van Veldhuisen DJ (2006) A single bolus of a long-acting erythropoietin analogue darbepoetin-alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20(2):135–141

    Article  PubMed  CAS  Google Scholar 

  55. Liem A, van de Woestijne AP, Bruijns E, Roeters van Lennep HW, de Boo JA, van Halteren HK, van Es TP, Jukema JW, van der Laarse A, Zwinderman AH, van Veldhuisen DJ (2009) Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol 131(2):285–287, Epub 2007 Nov 1

    Article  PubMed  Google Scholar 

  56. Binbrek AS, Mittal B, Rao KN, Sobel BE (2007) The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron Artery Dis 18(7):583–585, Review

    Article  PubMed  Google Scholar 

  57. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE (2009) Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST segment elevation acute myocardial infarction. Am J Cardiol 104(8):1035–1040

    Article  PubMed  CAS  Google Scholar 

  58. Ozawa T, Toba K, Suzuki H, Kato K, Iso Y, Akutsu Y, Kobayashi Y, Takeyama Y, Kobayashi N, Yoshimura N, Akazawa K, Aizawa Y, EPO/AMI-I Pilot Study Researchers (2010) Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction—randomized controlled pilot trial of EPO/AMI-1 study. Circ J 74(7):1415–1423

    Article  PubMed  CAS  Google Scholar 

  59. Yoshimura N, Toba K, Ozawa T, Aizawa Y, Hosoya T (2010) A novel program to accurately quantify infarction volume by (99 m)Tc MIBI SPECT, and its application for re-analyzing the effect of erythropoietin administration in patients with acute myocardial infarction. Circ J 74(12):2741–2743

    Article  PubMed  Google Scholar 

  60. Belonje AM, Voors AA, van Gilst WH, Anker SD, Slart RH, Tio RA, Zijlstra F, van Veldhuisen DJ, HEBE III investigators (2008) Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J 155(5):817–822

    Article  PubMed  CAS  Google Scholar 

  61. Voors AA, Belonje AM, Zijlstra F, Hillege HL, Anker SD, Slart RH, Tio RA, van’t Hof A, Jukema JW, Peels HO, Henriques JP, Ten Berg JM, Vos J, van Gilst WH, van Veldhuisen DJ, HEBE III Investigators (2010) A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 31(21):2593–2600

    Article  PubMed  CAS  Google Scholar 

  62. Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A, REVIVAL-3 Study Investigators (2010) Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv 3(5):408–413

    Article  PubMed  CAS  Google Scholar 

  63. Taniguchi N, Nakamura T, Sawada T, Matsubara K, Furukawa K, Hadase M, Nakahara Y, Nakamura T, Matsubara H (2010) Erythropoietin prevention trial of coronary restenosis and cardiac remodeling after ST-elevated acute myocardial infarction (EPOC-AMI): a pilot, randomized, placebo-controlled study. Circ J 74(11):2365–2371

    Article  PubMed  Google Scholar 

  64. Melloni C, Rao SV, Povsic TJ, Melton L, Kim RJ, Kilaru R, Patel MR, Talan M, Ferrucci L, Longo DL, Lakatta EG, Najjar SS, Harrington RA (2010) Design and rationale of the reduction of infarct expansion and ventricular remodeling with erythropoietin after large myocardial infarction (REVEAL) trial. Am Heart J 160(5):795–803, e2

    Article  PubMed  Google Scholar 

  65. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, Gruberg L, Hasselblad V, Greenbaum AB, Patel M, Kim RJ, Talan M, Ferrucci L, Longo DL, Lakatta EG, Harrington RA, REVEAL Investigators (2011) Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA 305(18):1863–1872

    Article  PubMed  CAS  Google Scholar 

  66. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C, Campanelli R, Bertoletti A, De Ferrari GM, Klersy C, Angoli L, Bramucci E, Marinoni B, Ferlini M, Moretti E, Raisaro A, Repetto A, Schwartz PJ, Tavazzi L (2011) High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol 147(1):124–131

    Article  PubMed  Google Scholar 

  67. Andreotti F, Agati L, Conti E, Santucci E, Rio T, Tarantino F, Natale L, Berardi D, Mattatelli A, Musumeci B, Bonomo L, Volpe M, Crea F, Autore C (2009) Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of Exogenous erythroPoietin in Acute Myocardial Infarction: New Outlook aNd Dose Association Study (EPAMINONDAS). J Thromb Thrombolysis 28(4):489–495

    Article  PubMed  CAS  Google Scholar 

  68. Ahmet I, Lakatta EG, Talan MI (2011) Therapeutic window for cardioprotection by recombinant human erythropoietin (rhEPO) in the rat model of ischemia-reperfusion: implications for clinical trial design. AHA 2011, Abstract

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cardiovascular Sciences, National Institute on Aging, NIH, Baltimore, MD, USA

    Mark I. Talan

  2. Department of Cardiovascular Research, Istituto Mario Negri, Milan, Italy

    Roberto Latini

Authors
  1. Mark I. Talan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Latini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical School, Brighton and Sussex, Trafford Centre, Falmer, BN1 9RY, United Kingdom

    Pietro Ghezzi

  2. Leiden University Medical Center, Stille Rijn 11a, Leiden, 2312 DE, Netherlands

    Anthony Cerami

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Talan, M.I., Latini, R. (2013). Myocardial Infarction: Cardioprotection by Erythropoietin. In: Ghezzi, P., Cerami, A. (eds) Tissue-Protective Cytokines. Methods in Molecular Biology, vol 982. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-308-4_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-308-4_17

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-307-7

  • Online ISBN: 978-1-62703-308-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation